Kathryn Logronio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kathryn Logronio has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Angus M. Sinclair
IGM Biosciences, Inc., Mountain View, California
15 shared publications - Avneesh K. Saini
IGM Biosciences, Inc., Mountain View, California
15 shared publications - Beatrice T. Wang
IGM Biosciences, Inc., Mountain View, California
15 shared publications - Bruce A. Keyt
IGM Biosciences, Mountain View, USA
15 shared publications - Carolyn R. Denson
IGM Biosciences, Inc., Mountain View, California
15 shared publications - Daniel Santos
IGM Biosciences, Inc., Mountain View, California
15 shared publications
Latest Publications
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
Supplementary Table S1 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
Supplementary Table S1 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
Supplemental Figure 5. T cells are exhausted in vitro with anti-CD3/CD28 beads prior to the MLR assay
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
Supplemental Figure 5. T cells are exhausted in vitro with anti-CD3/CD28 beads prior to the MLR assay
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S12 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
Supplemental Figure 12. IGM-7354 preferentially induces the proliferation of CD8+ T cells in cynomolgus monkeys.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
Supplemental Figure 12. IGM-7354 preferentially induces the proliferation of CD8+ T cells in cynomolgus monkeys.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
Supplemental Figure 7. IGM-7354 promotes the killing of MDA-MB-231 tumor cells in vitro and preferentially modulates CD8+ T cells.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
Supplemental Figure 7. IGM-7354 promotes the killing of MDA-MB-231 tumor cells in vitro and preferentially modulates CD8+ T cells.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Data from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
IgM antibodies are preformed pentameric or hexameric molecules that can be engineered to generate high-affinity and high-avidity fully human antibody therapeutics. In this study, we report an immunocytokine, IGM-7354, which was designed to bind multiple PD-L1 receptors while trans-presenting a single IL15/IL15Rα complex on the joining chain to IL15Rβγ-expressing cytotoxic NK and CD8+ T cells. We evaluated the pharmacologic and antitumor properties of IGM-7354 in preclinical models. IGM-7354 induced potent proliferation of NK and CD8+ T cells, both in vitro using healthy human peripheral blood mononuclear cells and in vivo in humanized mice, through the IL15/IL15Rα complex. In a mixed-lymphocyte reaction assay with exhausted human T cells, IGM-7354 restored the secretion of IFNγ compared with the IL15/IL15Rα complex or anti–PD-L1 alone, suggesting a rescue of exhausted T cells in vitro. Robust single-agent activity was observed in the humanized PD-L1+ MDA-MB-231 breast cancer mouse model. Antitumor responses were enhanced by adding IGM-7354 to the anti-CD38 daratumumab in RPMI-8226 multiple myeloma or anti-CD19 chimeric antigen receptor T-cell therapies in Raji lymphoma models. Finally, in cynomolgus monkeys, pharmacodynamic activity of increased NK and CD8+ T-cell proliferation was observed in multiple tissue compartments. Taken together, this study demonstrates the feasibility of developing a safe and effective IgM-based immunocytokine for the treatment of cancer, exploiting the multivalency of an IgM antibody to bind PD-L1 with high affinity and avidity and stimulate NK and CD8+ T-cell effectors.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
IgM antibodies are preformed pentameric or hexameric molecules that can be engineered to generate high-affinity and high-avidity fully human antibody therapeutics. In this study, we report an immunocytokine, IGM-7354, which was designed to bind multiple PD-L1 receptors while trans-presenting a single IL15/IL15Rα complex on the joining chain to IL15Rβγ-expressing cytotoxic NK and CD8+ T cells. We evaluated the pharmacologic and antitumor properties of IGM-7354 in preclinical models. IGM-7354 induced potent proliferation of NK and CD8+ T cells, both in vitro using healthy human peripheral blood mononuclear cells and in vivo in humanized mice, through the IL15/IL15Rα complex. In a mixed-lymphocyte reaction assay with exhausted human T cells, IGM-7354 restored the secretion of IFNγ compared with the IL15/IL15Rα complex or anti–PD-L1 alone, suggesting a rescue of exhausted T cells in vitro. Robust single-agent activity was observed in the humanized PD-L1+ MDA-MB-231 breast cancer mouse model. Antitumor responses were enhanced by adding IGM-7354 to the anti-CD38 daratumumab in RPMI-8226 multiple myeloma or anti-CD19 chimeric antigen receptor T-cell therapies in Raji lymphoma models. Finally, in cynomolgus monkeys, pharmacodynamic activity of increased NK and CD8+ T-cell proliferation was observed in multiple tissue compartments. Taken together, this study demonstrates the feasibility of developing a safe and effective IgM-based immunocytokine for the treatment of cancer, exploiting the multivalency of an IgM antibody to bind PD-L1 with high affinity and avidity and stimulate NK and CD8+ T-cell effectors.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
Supplementary Figure 2. Binding properties of IGM-7354.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
Supplementary Figure 2. Binding properties of IGM-7354.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
Supplemental Figure 8. Characterization of the role of targeted vs untargeted IL-15 IgM antibodies.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
Supplemental Figure 8. Characterization of the role of targeted vs untargeted IL-15 IgM antibodies.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S10 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
Supplemental Figure 10. Proliferation of mouse NK and CD8+ T cells were observed in presence of IGM7354.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
Supplemental Figure 10. Proliferation of mouse NK and CD8+ T cells were observed in presence of IGM7354.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S11 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
Supplemental Figure 11. IGM-7354 enhances the CAR-T anti-tumor responses in a dose-dependent manner.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
Supplemental Figure 11. IGM-7354 enhances the CAR-T anti-tumor responses in a dose-dependent manner.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
Supplemental Figure 3. IGM-7354 preferentially expands NK and CD8+ T cells in vitro.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells
Supplemental Figure 3. IGM-7354 preferentially expands NK and CD8+ T cells in vitro.